Regeneron Pharmaceuticals Inc. buy The Goldman Sachs Group, Inc.
Start price
14.04.25
/
50%
€500.00
Target price
14.04.26
€805.31
Performance (%)
29.17%
Price
09:19
€643.20
Summary
This prediction is currently active. The BUY prediction by The_Goldman_Sachs_Gr currently has a performance of 29.17%. A total of €2.64 was paid as dividends for this prediction. This prediction currently runs until 14.04.26. The prediction end date can be changed by The_Goldman_Sachs_Gr at any time. The_Goldman_Sachs_Gr has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Regeneron Pharmaceuticals Inc. | 5.956% | 5.956% |
| iShares Core DAX® | 0.795% | 1.458% |
| iShares Nasdaq 100 | -3.088% | -0.762% |
| iShares Nikkei 225® | -0.952% | -2.268% |
| iShares S&P 500 | -1.393% | 0.199% |
Comments by The_Goldman_Sachs_Gr for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $1,019.00 to $917.00. They now have a "buy" rating on the stock.
Ratings data for REGN provided by MarketBeat
Stopped prediction by The_Goldman_Sachs_Gr for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€524.00
30.04.25
30.04.25
€707.12
30.04.26
30.04.26
23.14%
09:19
09:19
